Johnson & Johnson's Xarelto treatment posted a 30.7% increase in sales in the second quarter, while Invokana sales jumped to $318 million from $117 million a year earlier. "J&J Lifts Earnings Outlook Despite Stronger Dollar, Competition--Update" at 8:25 a.m. misstated the increases.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Johnson and Johnson Charts.